Evidence map›Paper›PMID 39587836›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Enhancing the Therapeutic Potential of Peptide Antibiotics Using Bacteriophage Mimicry Strategies.

Hongping Wan, Xinyi Zhong, Shinong Yang, Jiarong Deng, Xu Song, Yong Liu, Yuanfeng Li, Zhongqiong Yin, Xinghong Zhao

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hongping WanCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0009-0002-3976-860X
Xinyi ZhongCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0009-0008-7866-5164
Shinong YangCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0009-0001-3638-8786
Jiarong DengCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0009-0003-1636-6867
Xu SongCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0000-0003-4102-0836
Yong LiuState Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, 300071, China.ORCID https://orcid.org/0000-0003-1738-7857
Yuanfeng LiTranslational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.ORCID https://orcid.org/0009-0002-9139-3139
Zhongqiong YinCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0000-0003-1752-644X
Xinghong ZhaoCenter for Sustainable Antimicrobials, Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, 611130, China.ORCID https://orcid.org/0000-0003-2366-3360

Funding

1000 Talents Sichuan Program 19231000 Talents Sichuan Program 2287National Key Research and Development Program 2023YFB3809902National Natural Science Foundation of China 22275043National Natural Science Foundation of China 32102689National Natural Science Foundation of China 52203184Sichuan Province Science and Technology Support Program 2022YFH0057Sichuan Province Science and Technology Support Program 2022YFH0062Sichuan Province Science and Technology Support Program 2022ZYD0068Sichuan Province Science and Technology Support Program 2024NSFSC2060
6 · The paper itself

Abstract

The rise of antibiotic resistance, coupled with a dwindling antibiotic pipeline, presents a significant threat to public health. Consequently, there is an urgent need for novel therapeutics targeting antibiotic-resistant pathogens. Nisin, a promising peptide antibiotic, exhibits potent bactericidal activity through a mechanism distinct from that of clinically used antibiotics. However, its cationic nature leads to hemolysis and cytotoxicity, which has limited its clinical application. Here, nanodelivery systems have been developed by mimicking the mechanisms bacteriophages use to deliver their genomes to host bacteria. These systems utilize bacteriophage receptor-binding proteins conjugated to loading modules, enabling efficient targeting of bacterial pathogens. Peptide antibiotics are loaded via dynamic covalent bonds, allowing for infection microenvironment-responsive payload release. These nanodelivery systems demonstrate remarkable specificity against target pathogens and effectively localize to bacteria-infected lungs in vivo. Notably, they significantly reduce the acute toxicity of nisin, rendering it suitable for intravenous administration. Additionally, these bacteriophage-mimicking nanomedicines exhibit excellent therapeutic efficacy in a mouse model of MRSA-induced pneumonia. The facile synthesis, potent antimicrobial performance, and favorable biocompatibility of these nanomedicines highlight their potential as alternative therapeutics for combating antibiotic-resistant pathogens. This study underscores the effectiveness of bacteriophage mimicry as a strategy for transforming peptide antibiotics into viable therapeutics.

Indexed as

Anti-Bacterial AgentsBacteriophagesNisinAnimalsHumansMethicillin-Resistant Staphylococcus aureusMiceAnti-Bacterial AgentsNisinantibiotic deliveryantibiotic resistanceantimicrobial peptidebacteriophage mimicrynanodelivery system

Identifiers

PMID39587836
PMCPMC11744576

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.